Basiliximab-Induced Non-Cardiogenic Pulmonary Edema in a Kidney Transplant Patient

Y. J. Lee, B. Park, Sihyung Park, K. Park, Jin Han Park, I. Park, Y. Kim
{"title":"Basiliximab-Induced Non-Cardiogenic Pulmonary Edema in a Kidney Transplant Patient","authors":"Y. J. Lee, B. Park, Sihyung Park, K. Park, Jin Han Park, I. Park, Y. Kim","doi":"10.4285/JKSTN.2018.32.3.63","DOIUrl":null,"url":null,"abstract":"Induction therapy with basiliximab is widely administered after kidney transplantation to prevent acute rejection. Herein, we report a case of non-cardiogenic pulmonary edema induced by basiliximab. To the best of our knowledge, such case has not been reported to date in Korea. A 54-year-old man with polycystic kidney disease received kidney transplantation. As induction therapy, he was prescribed basiliximab. On day 4, the second dose of basiliximab was administered. The patient complained of acute hypoxia 23 hours later, which led to circulatory collapse. He was discharged 3 weeks later with stable renal function. Pulmonary edema was presumed to have been caused by increased pulmonary capillary permeability. A possible hypothesis for this event occurring after the second basiliximab injection is steroid-related effects. Non-cardiogenic pulmonary edema is a complication that might occur after basiliximab induction therapy. Physicians should be aware of this potentially life-threatening complication.","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"102 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of The Korean Society for Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4285/JKSTN.2018.32.3.63","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Induction therapy with basiliximab is widely administered after kidney transplantation to prevent acute rejection. Herein, we report a case of non-cardiogenic pulmonary edema induced by basiliximab. To the best of our knowledge, such case has not been reported to date in Korea. A 54-year-old man with polycystic kidney disease received kidney transplantation. As induction therapy, he was prescribed basiliximab. On day 4, the second dose of basiliximab was administered. The patient complained of acute hypoxia 23 hours later, which led to circulatory collapse. He was discharged 3 weeks later with stable renal function. Pulmonary edema was presumed to have been caused by increased pulmonary capillary permeability. A possible hypothesis for this event occurring after the second basiliximab injection is steroid-related effects. Non-cardiogenic pulmonary edema is a complication that might occur after basiliximab induction therapy. Physicians should be aware of this potentially life-threatening complication.
肾移植患者巴昔昔单抗诱导的非心源性肺水肿
巴厘昔单抗诱导治疗在肾移植后广泛应用,以防止急性排斥反应。在此,我们报告一例非心源性肺水肿由巴昔昔单抗诱导。据我们所知,到目前为止,在韩国还没有这样的病例报告。一例54岁男性多囊肾病患者接受肾移植手术。作为诱导治疗,他开了basiliximab。第4天给予第2剂basiliximab。23小时后患者主诉急性缺氧,导致循环衰竭。3周后肾功能稳定出院。肺水肿被认为是由肺毛细血管通透性增加引起的。第二次注射basiliximab后发生这种事件的一个可能的假设是类固醇相关作用。非心源性肺水肿是巴昔昔单抗诱导治疗后可能发生的并发症。医生应该意识到这种潜在的危及生命的并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信